Roche Drug Outshines Amgen, Bristol Rivals in Lung Cancer Study

A Roche Holding AG drug billed as a potential blockbuster helped patients with a form of lung cancer that had spread live almost six months longer than two competitive medicines.

MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.swissinfo.ch)